Diabetes & metabolism
Clinical research into diabetes, insulin therapy and metabolic disorders, with the aim of advancing evidence-based treatment.
THOMAS PIEBER / RESEARCH
Diabetes, metabolism and medical technologies: research connected to clinical care.
Thomas Pieber’s scientific work connects questions in diabetes care with new therapeutic and technological approaches. The selected publications illustrate different perspectives: insulin pharmacology and disease-modifying approaches in type 1 diabetes.
Medical University of Graz02 / MEDICINE & RESEARCH
Clinical research into diabetes, insulin therapy and metabolic disorders, with the aim of advancing evidence-based treatment.
Glucose sensing and technological approaches to diabetes care connect medical questions with precise measurement.
Translating a medical research question into a practical diagnostic solution is also at the heart of the involvement in Elyte Diagnostics.
Pieber TR et al. · A clinical investigation of the pharmacology of once-weekly basal insulin in type 2 diabetes. The study examines concentration profiles and glucose-lowering effects, not long-term clinical outcomes.
von Herrath M et al., including Thomas R. Pieber · A randomised phase 2 trial investigating preservation of beta-cell function in recent-onset type 1 diabetes. An example of disease-modifying research, not an established cure.
A selection, not a complete publication list. Findings apply to the respective research question and study population.
CBMED / RESEARCH INTO PRACTICE
CEO at CBmed, together with Robert Lobnig
CBmed connects clinical and biomedical research with patient-focused application. As CEO, Thomas Pieber contributes his experience in an environment where academic institutions, healthcare providers and industry partners work together.
Translational biomarker research and precision medicine are central themes at CBmed. Biomarkers are measurable biological characteristics that can, for example, help characterise diseases or investigate treatments.
Discover CBmedOfficial CBmed update on the leadership role
CBmed and Elyte Diagnostics are presented as separate engagements; no partnership between the two is implied.
PROGRESS STARTS WITH A CONVERSATION.
Interested in Elyte Diagnostics as an investor, or in discussing the scientific work? Thomas Pieber welcomes a personal conversation.
Request an investor conversation thomas.pieber@medunigraz.atMore ways to get in touch